Browsing Tag
Dyne Therapeutics Inc.
1 post
Dyne’s FORCE RNA therapy reversed muscle damage in mice, and its first FSHD trial is now cleared
DYNE-302 enters clinical development after FDA clearance as Dyne expands its FORCE pipeline following a $431.4 million equity raise.